Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Islet Cell × motesanib diphosphate × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Vipoma 1 Somatostatinoma 1 Neuroendocrine Tumors 1 Neoplasms 1 Insulinoma 1 Glucagonoma 1 Gastrinoma 1 Carcinoma, Islet Cell 1 Adenoma, Islet Cell 1

Interventions

Octreotide 2 motesanib diphosphate 1 cixutumumab 1 batifiban 1 Oxaliplatin 1 Leucovorin 1 Fluorouracil 1 Everolimus 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed

46 enrolled 7 charts

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡